Sei Investments Co. Sells 3,701 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Sei Investments Co. lessened its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 6.6% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 52,097 shares of the biotechnology company’s stock after selling 3,701 shares during the period. Sei Investments Co. owned 0.12% of United Therapeutics worth $18,383,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Wealthfront Advisers LLC grew its stake in shares of United Therapeutics by 2,090,573.5% during the 4th quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company’s stock valued at $6,462,018,000 after acquiring an additional 18,313,424 shares during the period. Geode Capital Management LLC lifted its holdings in United Therapeutics by 4.3% during the third quarter. Geode Capital Management LLC now owns 1,094,015 shares of the biotechnology company’s stock valued at $391,459,000 after purchasing an additional 45,566 shares in the last quarter. FMR LLC boosted its position in shares of United Therapeutics by 41.1% in the third quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock worth $386,168,000 after purchasing an additional 314,004 shares during the period. Pacer Advisors Inc. increased its stake in shares of United Therapeutics by 5.5% in the fourth quarter. Pacer Advisors Inc. now owns 597,634 shares of the biotechnology company’s stock worth $210,869,000 after purchasing an additional 30,931 shares in the last quarter. Finally, Janus Henderson Group PLC raised its position in shares of United Therapeutics by 12.3% during the 3rd quarter. Janus Henderson Group PLC now owns 460,419 shares of the biotechnology company’s stock valued at $164,978,000 after purchasing an additional 50,409 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Trading Down 0.9 %

Shares of NASDAQ:UTHR opened at $308.02 on Friday. The company has a market cap of $13.83 billion, a price-to-earnings ratio of 13.53, a PEG ratio of 0.97 and a beta of 0.64. United Therapeutics Co. has a 12 month low of $221.53 and a 12 month high of $417.82. The company has a 50-day moving average price of $341.10 and a 200 day moving average price of $355.98.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping analysts’ consensus estimates of $6.10 by $0.09. The firm had revenue of $735.90 million during the quarter, compared to analysts’ expectations of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same quarter in the previous year, the business earned $4.36 EPS. As a group, equities analysts forecast that United Therapeutics Co. will post 24.48 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. StockNews.com downgraded shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. UBS Group increased their target price on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Finally, HC Wainwright restated a “buy” rating and set a $425.00 target price on shares of United Therapeutics in a research report on Thursday, February 27th. One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $388.25.

Insiders Place Their Bets

In other news, Director Nilda Mesa sold 255 shares of the company’s stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $355.77, for a total transaction of $90,721.35. Following the transaction, the director now owns 5,528 shares of the company’s stock, valued at approximately $1,966,696.56. This represents a 4.41 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Tommy G. Thompson sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $318.80, for a total value of $797,000.00. Following the sale, the director now directly owns 8,480 shares of the company’s stock, valued at $2,703,424. This represents a 22.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 82,755 shares of company stock valued at $29,792,021 over the last three months. 11.90% of the stock is owned by company insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.